A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The current clinical trial shall clarify a synergistic effect with regards to efficiency by
the combination of intratumoral injection of interleukin-2 (IL-2) and the intra-venous
application of ipilimumab.